A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells

Biochemical and Biophysical Research Communications

Volumn 274, Issue 1, 2000, Pages 136-141

  Freemerman, Alex J ^a   Powis, Garth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Apoptosis; Dexamethasone; Redox inactive; Thioredoxin; WEHI7.2 cells

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MUTANT PROTEIN; STAUROSPORINE; THIOREDOXIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; DNA TRANSFECTION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

EID: 0033931514     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.3091     Document Type: Article

References (39)

1. Holmgren A. Thioredoxin. Ann. Rev. Biochem. 54:1985;237-271.
2. Follmann H., Haberlein I. Thioredoxin: Universal, yet specific thiol-disulfide redox cofactors. BioFactors. 5:1995;147-156.
3. Gasdaska P. Y., Oblong J. E., Cotgreave I. A., Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta. 1218:1994;292-296.
4. Laurent T. C., Moore E. C., Reichard P. Enzymatic synthesis of deoxyribonucleotides. VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 239:1964;3436-3444.
5. Hayashi T., Ueno Y., Okamoto T. Oxidoreductive regulation of nuclear factor κB: Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268:1993;11380-11388.
6. Makino Y., Okamoto K., Yoshikawa N., Aoshima M., Hirota K., Yodoi J., Umesono K., Makino I., Tanaka H. Thioredoxin: A redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J. Clin. Invest. 98:1996;2469-2477.
7. Makino Y., Yoshikawa N., Okamoto K., Hirota K., Yodoi J., Makino I., Tanaka H. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J. Biol. Chem. 274:1999;3182-3188.
8. Freemerman A. J., Gallegos A., Powis G. NF-κB transactivation is increased but not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res. 59:1999;4090-4094.
9. Abate C., Patel I., Rauscher F. J., Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 249:1990;1157-1161.
10. Rubartelli A., Bajetto A., Allavena G., Wollman E., Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J. Biol. Chem. 267:1992;24161-24164.
11. Gasdaska J. R., Berggren M., Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 6:1995;1643-1650.
12. Wakasugi N., Tagaya Y., Wakasugi A., Mitsui M., Maeda M., Yodoi J., Tursz T. Adult T-cell leukemia-derived factor thioredoxin produced by both human T-lymphotropic virus type 1 and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2. Proc. Natl. Acad. Sci. USA. 87:1990;8282-8286.
13. Powis G., Gasdaska J. R., Baker A. Redox signalling and the control of cell growth and death. Adv. Pharmacol. 38:1997;329-359.
14. Tagaya Y., Maeda Y., Mitsui A., Kondo N., Matsui H., Hamuro J., Brown N., Arai K.-I., Yokota T., Wakasugi H., Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin: Possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 8:1989;757-764.
15. Powis G., Gasdaska J. R., Gasdaska P. Y., Berggren M., Kirkpatrick D. L., Engman L., Cotgreave I. A., Angulo M., Baker A. Selenium and the thioredoxin redox system: Effects on cell growth and death. Oncol. Res. 9:1997;303-312.
16. Berggren M., Gallegos A., Gasdaska J. R., Gasdaska P. Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:1996;3459-3466.
17. Fujii S., Nanbu Y., Nonogaki H., Konishi I., Mori T., Masutani H., Yodoi J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer. 68:1991;1583-1591.
18. Nakamura H., Masutani H., Tagaya Y., Yamauchi A., Inamoto T., Nanbu Y., Fujii S., Ozawa K., Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer. 69:1992;2091-2097.
19. Kawahara N., Tanaka T., Yokomizo A., Nanri H., Ono M., Wada M., Kohno K., Takenaka K., Sugimachi K., Kuwano M. Enhanced coexpression of thioredixin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 56:1996;5330-5333.
20. Wakita H., Yodoi J., Masutani H., Toda K., Takigawa M. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions. J. Invest. Dermatol. 99:1992;101-107.
21. Grogan T., Fenoglio-Priser C., Zaheb R., Bellamy W., Vela E., Richter L., Powis G. Overexpression of thioredoxin, a putative oncogene, in gastric carcinoma with associated change in proliferation and apoptosis. J. Pathol. 2000.
22. Gallegos A., Gasdaska J. R., Taylor C. W., Paine-Murrieta G. D., Goodman D., Gasdaska P. Y., Berggren M., Briehl M. M., Powis G. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res. 56:1996;5765-5770.
23. Baker A., Payne C. M., Briehl M. M., Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 57:1997;5162-5167.
24. Wang J., Kobayashi M., Sakurada K., Imamura M., Moriuchi T., Hosokawa M. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin. Blood. 89:1997;2480-2487.
25. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin and etoposide. Cancer Res. 55:1995;4293-4296.
26. Sasada T., Iwata S., Sato N., Kitaoka Y., Hirota K., Nakamura K., Nishiyama A., Taniguchi Y., Takabayashi A., Yodoi J. Redox control of resistance to cis-diamminedichloroplatinum(II) (CDDP): Protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest. 97:1996;2268-2276.
27. Yamada M., Tomida A., Yoshikawa H., Taketani Y., Tsuruo T. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines. Cancer Chemother. Pharmacol. 40:1997;31-37.
28. Oblong J. E., Berggren M., Gasdaska P. Y., Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J. Biol. Chem. 269:1994;11714-11720.
29. Baker A. F., Briehl M. M., Dorr R., Powis G. Decreased antioxidant defense and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 selectively prevents the loss of catalase activity. Cell Death Differ. 3:1996;207-213.
30. Kruman I., Guo Q., Mattson M. P. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J. Neurosci. Res. 51:1998;293-308.
31. Sinha B. K., Eliot H. M., Kalayanaraman B. Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. FEBS Lett. 227:1988;240-244.
32. 2 upon thioredoxin-enriched lens epithelial cells. J. Biol. Chem. 263:1988;4984-4990.
33. Briehl M. M., Cotgreave I. A., Powis G. Downregulation of the antioxidant defense during glucocorticoid-mediated apoptosis. Cell Death Differ. 2:1995;41-46.
34. Chae H. Z., Chung S. J., Rhee S. G. Thioredoxin-dependent peroxide reductase from yeast. J. Biol. Chem. 269:1994;27670-27678.
35. Jin D., Zoon H. J., Rhee S. G., Jeang K. Regulatory role for a novel human thioredoxin peroxidase in NF-κB activation. J. Biol. Chem. 272:1997;30952-30961.
36. Shau H., Kim A. T., Hedrick C. C., Lusis A. J., Tompkins C., Finney R., Leung D. W., Paglia D. E. Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses. Free Radical Biol. Med. 22:1997;497-507.
37. Van Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274:1996;787-791.
38. Schenk H., Klein M., Erdbrügger W., Dröge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc. Natl. Acad. Sci. USA. 91:1994;1672-1676.
39. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1:1998;2596-2606.